Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects-Reference-Cited by-同舟云学术

Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects

Published:2022-03-10 Issue:4 Volume:30 Page:360-367
ISSN:1976-9148
Container-title:Biomolecules & Therapeutics
language:en
Short-container-title:Biomol Ther (Seoul)

Author:

Lee Hyo Jeong¹,Moon Yeongyu²,Choi Jungil²,Heo Jeong Doo²,Kim Sekwang¹,Nallapaneni Hari Krishna³,Chin Young-Won⁴,Lee Jongkook³,Han Sun-Young¹

Affiliation:

1. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea

2. Gyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, Republic of Korea

3. College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea

4. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea

Funder

National Research Foundation of Korea

Publisher

The Korean Society of Applied Pharmacology

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pdf.medrang.co.kr/BT2/2022/030/BT030-04-360.pdf

Reference32 articles.

1. Entrectinib: First Global Approval

2. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

3. Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

4. Bongarzone, I., Pierotti, M. A., Monzini, N., Mondellini, P., Manenti, G., Donghi, R., Pilotti, S., Grieco, M., Santoro, M. and Fusco, A. (1989) High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4, 1457-1462.

5. ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and anti-melanogenic efficacy of 2-mercaptobenzoxazoles with nanomolar tyrosinase activity inhibition;Bioorganic & Medicinal Chemistry;2024-08

2. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents;British Journal of Cancer;2024-06-20

3. Characterization of LTr1 derived from cruciferous vegetables as a novel anti-glioma agent via inhibiting TrkA/PI3K/AKT pathway;Acta Pharmacologica Sinica;2022-12-08